• 1
    Keck PE Jr, McElroy SL, Strakowski SM et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998; 155: 646652.
  • 2
    Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003; 73: 123131.
  • 3
    Coryell W, Endicott J, Maser JD, Mueller T, Lavori P, Keller M. The likelihood of recurrence in bipolar affective disorder: the importance of episode recency. J Affect Disord 1995; 33: 201206.
  • 4
    Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs 2005; 19: 557569.
  • 5
    Baldessarini RJ, Tondo L, Floris G, Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord 2000; 61: 1322.
  • 6
    Calabrese JR, Shelton MD, Rapport DJ, Kujawa M, Kimmel SE, Caban S. Current research on rapid cycling bipolar disorder and its treatment. J Affect Disord 2001; 67: 241255.
  • 7
    Calabrese JR, Shelton MD, Rapport DJ et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 21522161.
  • 8
    Bowden CL, Lecrubier Y, Bauer M et al. Maintenance therapies for classic and other forms of bipolar disorder. J Affect Disord 2000; 59(Suppl. 1): S57S67.
  • 9
    Suppes T, Brown E, Schuh LM, Baker RW, Tohen M. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. J Affect Disord 2005; 89: 6977.
  • 10
    Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad Med 2000; Spec No: 1–104.
  • 11
    Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003; 108: 414.
  • 12
    Seddon K, Nutt D. Pharmacological treatment of bipolar disorder. Psychiatry 2007; 6: 305308.
  • 13
    American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 4 (Suppl.): 150.
  • 14
    Gershing K, Burchett B, Kujawa M et al. Frequently relapsing bipolar disorder: characterization of psychiatric resource utilization by patients in a large healthcare database. Poster presented at: Society of Biological Psychiatry 62nd Annual Convention and Scientific Program, May 17–19, 2007, San Diego, CA, USA.
  • 15
    Keck PE Jr, McElroy SL, Strakowski SM, Bourne ML, West SA. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997; 33: 8791.
  • 16
    Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002; 105: 164172.
  • 17
    Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002; 63: 384390.
  • 18
    Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002; 159: 19271929.
  • 19
    Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006; 67(Suppl. 11): 2227.
  • 20
    International conference on harmonization, good clinical practice: consolidated guidelines. Fed Regist 1997; 62: 2569125709.
  • 21
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association, 2000.
  • 22
    Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429435.
  • 23
    Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382389.
  • 24
    Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159171.
  • 25
    Lindenmayer JP, Czobor P, Alphs L et al. The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res 2003; 63: 161170.
  • 26
    Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 1119.
  • 27
    Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672676.
  • 28
    Guy WA Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: U.S. Department of Health, Education and Welfare, 1972: 534537.
  • 29
    NNTs for stroke prevention. Bandolier 38 1997; 4: 2. Available at: Accessed June 20, 2008.
  • 30
    NNT for lipid lowering. Bandolier 41 1997; 4: 3. Available at: Accessed June 20, 2008.
  • 31
    Antiepileptic NNTs. Bandolier 54 1998; 5: 4. Available at: Accessed June 20, 2008.
  • 32
    Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 2006; 60: 933940.
  • 33
    Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007; 7: 40. Available at: Accessed November 3, 2009.
  • 34
    Storosum JG, Wohlfarth T, Schene A, Elferink A, Van Zwieten BJ, Van Dern Brink W. Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode. Bipolar Disord 2007; 9: 793798.
  • 35
    Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 11251132.
  • 36
    Fleischhacker WW, Eerdekens M, Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64: 12501257.
  • 37
    Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 2004; 83: 263275.
  • 38
    Simpson GM, Mahmoud RA, Lasser RA et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006; 67: 11941203.
  • 39
    Bowden CL, Myers JE, Grossman F, Xie Y. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J Clin Psychiatry 2004; 65: 707714.
  • 40
    Hirschfeld RM, Keck PE Jr, Kramer M et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161: 10571065.
  • 41
    Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159: 11461154.
  • 42
    Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141147.
  • 43
    Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005; 15: 7584.
  • 44
    McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006; 67(Suppl. 5): 1518.
  • 45
    Kupka RW, Luckenbaugh DA, Post RM et al. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry 2005; 162: 12731280.